TGFB1 and pancreatic neoplasm: We extended this observation to two additional TGF-β-induced EMT models, the pancreatic cancer cell line, PANC-1 and the NSCLC cell line, H358, as well to an acquired erlotinib resistance model (derived from HCC4006 NSCLC cells) that had undergone EMT independent of TGF-β [20].